{"id":47774,"date":"2022-08-29T22:01:44","date_gmt":"2022-08-29T20:01:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/"},"modified":"2022-08-29T22:01:44","modified_gmt":"2022-08-29T20:01:44","slug":"feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/","title":{"rendered":"Feinstein Institutes Researchers Identify Potential Drug to Treat Sepsis"},"content":{"rendered":"
\n

MANHASSET, N.Y.–(BUSINESS WIRE)–Each year, more than 48 million cases<\/a> of sepsis are diagnosed and account for 11 million deaths annually. Current sepsis treatment is limited; to address this clinical need researchers from the Feinstein Institutes for Medical Research<\/a> and Northwell Health\u2019s Department of Pediatrics and Cohen Children\u2019s Medical Center<\/a> published new research in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS)<\/a> indicating that stimulating the molecular target of a different blood pressure drug enhanced the immune response to sepsis.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nSepsis is a common and fatal condition when the body\u2019s regulatory control of the immune response to an infection is lost. As a result, the organ systems fail to function correctly, resulting in death. Current treatment relies on supporting the organs, for example, using drugs to correct low blood pressure and devices like mechanical ventilators. However, recent studies have shown that ventilators can damage the lungs and that norepinephrine, the standard of care medication used to treat blood pressure, may compromise the immune system, weakening the body\u2019s response.\n<\/p>\n

\nThe new research, led by the Feinstein Institutes\u2019 Matthew D. Taylor, MD<\/a>, and Mass General\u2019s Daniel E. Leisman, MD, examined the effects of angiotensin-II, a peptide hormone.\n<\/p>\n

\n\u201cThere are no specific drugs available to treat sepsis, and it turns out that the blood pressure drug of choice may interfere with the body\u2019s natural ability to contain infection,\u201d said Dr. Taylor, instructor in the Institute of Molecular Medicine<\/a> at the Feinstein Institutes, assistant professor of the Pediatrics Division of Pediatric Critical Care Medicine at Zucker School of Medicine at Hofstra\/Northwell<\/a> and co-principal investigator of the study. \u201cOur research demonstrates that angiotensin-II enhances some immune responses, improving bacterial clearance and suggests the need for future research to determine if the drug has similar effects in patients with sepsis and to compare angiotensin-II directly with standard care.\u201d\n<\/p>\n

\nThe results show that angiotensin-II, which increases blood pressure via a molecular pathway not affected by norepinephrine, directly stimulated immune responses and reduced bacteria counts in animal models. In contrast, the bacterial load increased when the septic mice received norepinephrine.\n<\/p>\n

\n\u201cSepsis is a deadly disorder whose underlying biology is poorly understood,\u201d said Clifford S. Deutschman, MD<\/a>, professor in the Institute of Molecular Medicine at the Feinstein Institutes and an internationally recognized expert on the disorder. \u201cThe work done by Drs. Taylor and Leisman is exciting and identifies a potential therapeutic option that should be explored further to improve care.\u201d\n<\/p>\n

\nAngiotensin-II is already Food and Drug Administration (FDA) approved for treating hypotension in shock and sepsis. This paves the way for future research, including clinical trials to study the effects of angiotensin-II.\n<\/p>\n

\n\u201cUnfortunately, current sepsis treatments, like norepinephrine and mechanical ventilation, have a downside,\u201d said Charles L. Schleien, MD<\/a>, senior vice president and chair of pediatric services at Northwell Health and professor in the Institute of Molecular Medicine at the Feinstein Institutes. \u201cThis new study will help guide future research in and out of the lab to help develop effective treatments against this frequently fatal condition.\u201d\n<\/p>\n

\nAdditional findings from the PNAS <\/i>report show that angiotensin-II alters the system\u2019s inflammatory response limiting systemic inflammation, promoting bacterial defense and reducing organ dysfunction.\n<\/p>\n

\n\u201cResearchers worldwide are beginning to unravel the underlying mechanisms of sepsis,\u201d said Kevin J. Tracey, MD<\/a>, president and CEO of the Feinstein Institutes. \u201cDrs. Taylor and Leisman\u2019s work contributes to our understanding of this deadly condition and opens up new avenues of research in the lab and clinical trials.\u201d\n<\/p>\n

\nAbout the Feinstein Institutes
\n
<\/i><\/b>The Feinstein Institutes for Medical Research<\/a><\/i><\/span> is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine \u2013 a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit<\/i> <\/i>http:\/\/feinstein.northwell.edu<\/a><\/i> <\/i>and follow us on<\/i> <\/i>LinkedIn<\/a>.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMatthew Libassi
\n
631-793-5325
\n
mlibassi@northwell.edu<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MANHASSET, N.Y.–(BUSINESS WIRE)–Each year, more than 48 million cases of sepsis are diagnosed and account for 11 million deaths annually. Current sepsis treatment is limited; to address this clinical need researchers from the Feinstein Institutes for Medical Research and Northwell Health\u2019s Department of Pediatrics and Cohen Children\u2019s Medical Center published new research in the journal … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47774","6":"format-standard","7":"category-industry"},"yoast_head":"\nFeinstein Institutes Researchers Identify Potential Drug to Treat Sepsis - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Feinstein Institutes Researchers Identify Potential Drug to Treat Sepsis - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MANHASSET, N.Y.–(BUSINESS WIRE)–Each year, more than 48 million cases of sepsis are diagnosed and account for 11 million deaths annually. Current sepsis treatment is limited; to address this clinical need researchers from the Feinstein Institutes for Medical Research and Northwell Health\u2019s Department of Pediatrics and Cohen Children\u2019s Medical Center published new research in the journal ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-29T20:01:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220829005673\/en\/1555909\/21\/Taylor.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Feinstein Institutes Researchers Identify Potential Drug to Treat Sepsis\",\"datePublished\":\"2022-08-29T20:01:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\\\/\"},\"wordCount\":725,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220829005673\\\/en\\\/1555909\\\/21\\\/Taylor.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\\\/\",\"name\":\"Feinstein Institutes Researchers Identify Potential Drug to Treat Sepsis - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220829005673\\\/en\\\/1555909\\\/21\\\/Taylor.jpg\",\"datePublished\":\"2022-08-29T20:01:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220829005673\\\/en\\\/1555909\\\/21\\\/Taylor.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220829005673\\\/en\\\/1555909\\\/21\\\/Taylor.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Feinstein Institutes Researchers Identify Potential Drug to Treat Sepsis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Feinstein Institutes Researchers Identify Potential Drug to Treat Sepsis - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/","og_locale":"en_US","og_type":"article","og_title":"Feinstein Institutes Researchers Identify Potential Drug to Treat Sepsis - Pharma Trend","og_description":"MANHASSET, N.Y.–(BUSINESS WIRE)–Each year, more than 48 million cases of sepsis are diagnosed and account for 11 million deaths annually. Current sepsis treatment is limited; to address this clinical need researchers from the Feinstein Institutes for Medical Research and Northwell Health\u2019s Department of Pediatrics and Cohen Children\u2019s Medical Center published new research in the journal ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-29T20:01:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220829005673\/en\/1555909\/21\/Taylor.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Feinstein Institutes Researchers Identify Potential Drug to Treat Sepsis","datePublished":"2022-08-29T20:01:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/"},"wordCount":725,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220829005673\/en\/1555909\/21\/Taylor.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/","url":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/","name":"Feinstein Institutes Researchers Identify Potential Drug to Treat Sepsis - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220829005673\/en\/1555909\/21\/Taylor.jpg","datePublished":"2022-08-29T20:01:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220829005673\/en\/1555909\/21\/Taylor.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220829005673\/en\/1555909\/21\/Taylor.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/feinstein-institutes-researchers-identify-potential-drug-to-treat-sepsis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Feinstein Institutes Researchers Identify Potential Drug to Treat Sepsis"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47774"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47774\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}